Kohei Shitara

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Yelena Y. Janjigian, Kohei Shitara, Markus Moehler et al. · The Lancet · 2021 · 2.7K citations · Full text

Chemotherapy Versus Chemotherapy, Esophageal Cancer, Gastrointestinal Oncology +7

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang et al. · The Lancet · 2018 · 1.3K citations · Full text

Pembrolizumab Versus Paclitaxel, Gastrointestinal Oncology, Medicine +7

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

Kohei Shitara, Yung‐Jue Bang, Satoru Iwasa et al. · New England Journal of Medicine · 2020 · 1.2K citations · Full text

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer

Kohei Shitara, Eric Van Cutsem, Yung‐Jue Bang et al. · JAMA Oncology · 2020 · 1.1K citations · Full text

PD-1 ⁺ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer

Takahiro Kamada, Yosuke Togashi, Christopher Tay et al. · Proceedings of the National Academy of Sciences · 2019 · 987 citations · Full text